Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer

Clinical Chemistry

Volumn 63, Issue 2, 2017, Pages 532-541

  Page, Karen ^a   Guttery, David S ^a   Fernandez Garcia, Daniel ^a   Hills, Allison ^b   Hastings, Robert K ^a   Luo, Jinli ^a   Goddard, Kate ^c   Shahin, Vedia ^c   Woodley Barker, Laura ^c   Rosales, Brenda M ^b   Coombes, R Charles ^b   Stebbing, Justin ^b   Shaw, Jacqueline A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA;

AMPLICON; ARTICLE; BLOOD SAMPLING; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA EXTRACTION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; HUMAN; LYMPHOCYTE; METASTATIC BREAST CANCER; NEXT GENERATION SEQUENCING; ONCOGENE NEU; POLYMERASE CHAIN REACTION; SOMATIC MUTATION; ADULT; AGED; BLOOD; BREAST TUMOR; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; METASTASIS; MIDDLE AGED; MUTATION; PARTICLE SIZE; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PARTICLE SIZE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 85011628861     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.261834     Document Type: Article

References (34)

1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
2. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, et al. Signatures of mutation and selection in the cancer genome. Nature 2010;463:893-8.
3. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 2008; 105:16224-9.
4. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
5. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 2016; 534:47-54.
6. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486:400-4.
7. Rehm HL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet 2013;14:295-300.
8. Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem 2015;61:974-82.
9. Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 2012;22:220-31.
10. Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, et al. Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach. Clin Chem 2015;61:838-49.
11. Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 2013;19:3276-84.
12. Page K, Guttery DS, Zahra N, Primrose L, Elshaw SR, Pringle JH, et al. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One 2013;8:e77963.
13. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, et al. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009;11:R24.
14. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
15. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-81.
16. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
17. Schwarz JM, Cooper DN, Schuelke M, Seelow D. Mutationtaster2: mutation prediction for the deepsequencing age. Nat Methods 2014;11:361-2.
18. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol 2011;29:24-6.
19. Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, et al. Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics 2014;30: 3443-50.
20. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 2011;27:2987-93.
21. Quinlan AR, Hall IM. Bedtools: A flexible suite of utilities for comparing genomic features. Bioinformatics 2010;26:841-2.
22. Primer3. http://primer3.ut.ee/ (Accessed January 2014).
23. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumorDNAto monitor metastatic breast cancer. N Engl J Med 2013;368: 1199-209.
24. Park RW, Kim TM, Kasif S, Park PJ. Identification of rare germline copy number variations over-represented in five human cancer types. Mol Cancer 2015;14:25.
25. Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 2015;7:313ra182.
26. Kirkizlar E, Zimmermann B, Constantin T, Swenerton R, Hoang B, Wayham N, et al. Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Transl Oncol 2015;8:407-16.
27. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.
28. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 2011;108:9530-5.
29. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. Beaming: Single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006;3:551-9.
30. Wentzensen N, Wacholder S. From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov 2013;3:148-57.
31. Page K, Hava N, Ward B, Brown J, Guttery DS, Ruangpratheep C, et al. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer 2011;104:1342-8.
32. Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, et al. Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin Cancer Res 2015;21:4586-96.
33. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 2015;163:506-19.
34. Park NI, Rogan PK, Tarnowski HE, Knoll JH. Structural and genic characterization of stable genomic regions in breast cancer: relevance to chemotherapy. Mol Oncol 2012;6:347-59.